ArticleCurrent addiction reports2014
Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.
Article in Current addiction reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.CNS drugs · 2018Pooled it
- Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology.Pharmacology, biochemistry, and behavior · 2019Trial
- Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.The American journal on addictions · 2018Trial
- Trial
- Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.Psychopharmacology · 2016Trial
- Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.Drug and alcohol dependence · 2016Trial
- Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- The interaction between Environmental Enrichment and fluoxetine in inhibiting sucrose-seeking renewal in mice depend on social living condition.Psychopharmacology · 2022Article
- Non-abstinent treatment outcomes for cannabis use disorder.Drug and alcohol dependence · 2021Article
- Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.Journal of neurochemistry · 2021Review
- Addiction and Sleep Disorders.Advances in experimental medicine and biology · 2021Article
- Addiction and Sleep Disorders.Advances in experimental medicine and biology · 2021Article
- Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.The Journal of pharmacology and experimental therapeutics · 2020Article
- Neuronal nicotinic acetylcholine receptors mediate ∆Addiction biology · 2020Article
- Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.Addiction biology · 2019Article
- Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.Addiction biology · 2019Article
- The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.Frontiers in psychiatry · 2019Review
- Cannabis Addiction and the Brain: a Review.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2018Review
- The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Review
- Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
With large and increasing numbers of people using cannabis, the development of cannabis use disorder (CUD) is a growing public health concern. Despite the success of evidence-based psychosocial therapies, low rates of initial abstinence and high rates of relapse during and following treatment for CUD suggest a need for adjunct pharmacotherapies. Here we review the literature on medication development for the treatment of CUD, with a particular focus on studies published within the last three years (2010-2013). Studies in both the human laboratory and in the clinic have tested medications with a wide variety of mechanisms. In the laboratory, the following medication strategies have been shown to decrease cannabis withdrawal and self-administration following a period of abstinence (a model of relapse): the cannabinoid receptor agonist, nabilone, and the adrenergic agonist, lofexidine, alone and in combination with dronabinol (synthetic THC), supporting clinical testing of these medication strategies. Antidepressant, anxiolytic and antipsychotic drugs targeting monoamines (norepinephrine, dopamine, and serotonin) have generally failed to decrease withdrawal symptoms or laboratory measures of relapse. In terms of clinical trials, dronabinol and multiple antidepressants (fluoxetine, venlafaxine and buspirone) have failed to decrease cannabis use. Preliminary results from controlled clinical trials with gabapentin and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.